Prospective Study of Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma Patients Who Are Not Suitable for Stem Cell Transplant or Multi-Agent Chemotherapy
British Journal of Haematology - United Kingdom
doi 10.1111/bjh.15539
Full Text
Open PDFAbstract
Available in full text
Categories
Date
August 30, 2018
Authors
Publisher
Wiley